The COX7B antibody targets cytochrome c oxidase subunit VIIb (COX7B), a nuclear-encoded subunit of mitochondrial complex IV (cytochrome c oxidase), which is the terminal enzyme in the mitochondrial electron transport chain (ETC). Complex IV catalyzes the transfer of electrons from cytochrome c to molecular oxygen, a critical step in oxidative phosphorylation and ATP production. COX7B, one of multiple tissue-specific isoforms of subunit VII, is ubiquitously expressed and plays a structural and regulatory role in complex IV assembly and function. Antibodies against COX7B are widely used in research to investigate mitochondrial respiration, cellular metabolism, and diseases linked to ETC dysfunction, such as mitochondrial disorders, neurodegenerative diseases, and cancer. They enable protein detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping to assess COX7B expression levels, subcellular localization, and potential dysregulation in pathological conditions. Studies have also explored COX7B's role in hypoxia responses, metabolic reprogramming in tumors, and rare genetic syndromes like microphthalmia with linear skin lesions (MLS), associated with COX7B mutations. These antibodies serve as essential tools for elucidating mitochondrial biology and its implications in health and disease.